Suppr超能文献

体重和脉搏变化:SCOUT试验中患有心血管疾病的超重和肥胖受试者的结局事件

Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.

作者信息

Seimon R V, Espinoza D, Finer N, James W P T, Legler U F, Coutinho W, Sharma A M, Van Gaal L, Maggioni A P, Sweeting A, Torp-Pedersen C, Gebski V, Caterson I D

机构信息

The Boden Institute of Obesity, Nutrition Exercise & Eating Disorders, University of Sydney, Sydney, New South Wales, Australia.

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.

出版信息

Int J Obes (Lond). 2015 May;39(5):849-57. doi: 10.1038/ijo.2014.211. Epub 2014 Dec 18.

Abstract

BACKGROUND/OBJECTIVES: The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. We examined the relationship between early changes (both increases and decreases) in pulse rate, and the impact of these changes on subsequent cardiovascular outcome events in both the placebo and sibutramine groups.

SUBJECTS/METHODS: 9804 males and females, aged ⩾55 years, with a body mass index of 27-45 kg m(-)(2) were included in this current subanalysis of the SCOUT trial. Subjects were required to have a history of cardiovascular disease and/or type 2 diabetes mellitus with at least one cardiovascular risk factor, to assess cardiovascular outcomes. The primary outcome event (POE) was a composite of nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest or cardiovascular death. Time-to-event analyses of the POE were performed using Cox regression models.

RESULTS

During the initial 6-week sibutramine treatment period, the induced pulse rate increase was related to weight change (1.9±7.7 beats per minute (bpm)  with weight increase; 1.4±7.3 bpm, 0-5 kg weight loss; 0.6±7.4 bpm, ⩾5 kg weight loss). Throughout the subsequent treatment period, those continuing on sibutramine showed a consistently higher mean pulse rate than the placebo group. There was no difference in POE rates with either an increase or decrease in pulse rate over the lead-in period, or during lead-in baseline to 12 months post randomization. There was also no relationship between pulse rate at lead-in baseline and subsequent cardiovascular events in subjects with or without a cardiac arrhythmia.

CONCLUSION

Baseline pulse rate and changes in pulse rate may not be an important modifier nor a clinically useful predictor of outcome in an individual elderly cardiovascular obese subject exposed to weight management.

摘要

背景/目的:西布曲明心血管结局(SCOUT)试验表明,在接受长期西布曲明治疗并配合饮食和运动的超重及肥胖受试者中,非致命性心血管事件的相对风险显著增加,但死亡率未增加。我们研究了心率早期变化(包括增加和降低)之间的关系,以及这些变化对安慰剂组和西布曲明组随后心血管结局事件的影响。

受试者/方法:本项SCOUT试验的亚分析纳入了9804名年龄≥55岁、体重指数为27 - 45 kg·m⁻²的男性和女性。受试者需有心血管疾病史和/或2型糖尿病史,并至少有一个心血管危险因素,以评估心血管结局。主要结局事件(POE)为非致命性心肌梗死、非致命性中风、心脏骤停复苏或心血管死亡的复合事件。使用Cox回归模型对POE进行事件发生时间分析。

结果

在最初6周的西布曲明治疗期内,诱发的心率增加与体重变化相关(体重增加时为1.9±7.7次/分钟(bpm);体重减轻0 - 5 kg时为1.4±7.3 bpm;体重减轻≥5 kg时为0.6±7.4 bpm)。在随后的整个治疗期内,继续服用西布曲明的患者平均心率始终高于安慰剂组。在导入期或从导入期基线到随机分组后12个月期间,心率增加或降低时的POE发生率没有差异。在有或无心律失常的受试者中,导入期基线心率与随后的心血管事件之间也没有关系。

结论

对于接受体重管理的老年心血管肥胖个体,基线心率和心率变化可能不是重要的预后影响因素,也不是临床有用的预后预测指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验